Journal
CANCER LETTERS
Volume 473, Issue -, Pages 25-32Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2019.12.029
Keywords
Liver cancer; Cancer vaccine; Immunotherapy; Checkpoint inhibitors; Epigenetic drugs
Categories
Funding
- EU FP7 Project Cancer Vaccine development for Hepatocellular Carcinoma - HEPAVAC [602893]
- Transcan2 - HEPAMUT project [643638]
- Italian Ministry of Health through Institutional Ricerca Corrente
- POR FESR 2014/2020 Campania OncoTerapie
- HEPAVAC
- Ricerca Corrente
- POR FESR 2014/2020 NanoCAN
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, there is a single drug approved as first-line systemic therapy in advanced unresectable HCC, providing a very limited survival benefit. In earlier stages, 5-year survival rates after surgical and loco-regional therapies are extremely variable depending on the stage of disease. Nevertheless, HCC is considered an immunogenic tumor arising in chronically inflamed livers. In such a scenario, immunotherapy strategies for HCC, in particular combinations including cancer vaccines, may represent a key therapeutic tool to improve clinical outcome in HCC patients. However, a lot of improvement is needed given the disappointing results obtained so far.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available